Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mussi

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Tumori|September 21, 2016
Sporadic desmoid tumors of the abdominal wall: the results of surgeryChiara E Mussi, Piergiuseppe Colombo, Chiara Lo Russo, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|May 20, 2021
In phantom evaluation of targeting accuracy in MRI-based brain radiosurgeryS Calusi, C Arilli, E Mussi, et al.
ESMO Open|May 23, 2025
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancerD S Hong, R-H Xu, L Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Tumori|September 21, 2016
Sporadic desmoid tumors of the abdominal wall: the results of surgeryChiara E Mussi, Piergiuseppe Colombo, Chiara Lo Russo, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|May 20, 2021
In phantom evaluation of targeting accuracy in MRI-based brain radiosurgeryS Calusi, C Arilli, E Mussi, et al.
ESMO Open|May 23, 2025
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancerD S Hong, R-H Xu, L Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2025
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancerChangsong Qi, Lin Shen, Thierry Andre, et al.
Pageof 1